Which antipsychotics cause gynaecomastia is an important clinical question for anyone prescribed these medications. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a recognised side effect of several antipsychotics, primarily driven by drug-induced hyperprolactinaemia. Typical antipsychotics such as haloperidol and chlorpromazine, along with atypical agents including risperidone, paliperidone, and amisulpride, carry the highest risk. Understanding the mechanism, recognising symptoms early, and knowing when to seek medical advice are essential for safe, informed prescribing and patient care.

How Antipsychotics Can Cause Gynaecomastia

Antipsychotics cause gynaecomastia by blocking dopamine D2 receptors, removing inhibition of prolactin release and causing hyperprolactinaemia, which shifts the oestrogen-to-androgen balance and promotes breast tissue growth.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a recognised side effect associated with certain antipsychotic medications. Understanding which antipsychotics cause gynaecomastia requires an appreciation of how these drugs interact with the body's hormonal systems.

Most antipsychotics work by blocking dopamine D2 receptors in the brain. In the tuberoinfundibular pathway, dopamine normally inhibits the release of prolactin from the anterior pituitary gland. When D2 receptors are blocked, this inhibitory effect is removed, leading to hyperprolactinaemia — elevated levels of prolactin in the bloodstream. Sustained hyperprolactinaemia can also suppress gonadal hormone production, reducing testosterone and shifting the oestrogen-to-androgen balance in a way that further promotes breast tissue growth. Together, these hormonal changes can result in gynaecomastia, as well as galactorrhoea (nipple discharge) and sexual dysfunction.

The antipsychotics most strongly associated with prolactin elevation and subsequent gynaecomastia include:

• Typical (first-generation) antipsychotics: Haloperidol, chlorpromazine, and fluphenazine are among the most potent D2 blockers and carry a high risk of hyperprolactinaemia. This is reflected in their UK Summary of Product Characteristics (SmPCs), available via the electronic Medicines Compendium (emc).

• Atypical (second-generation) antipsychotics: Risperidone and its active metabolite paliperidone are particularly well-documented causes of elevated prolactin and gynaecomastia, as noted in their respective SmPCs. Amisulpride also carries a significant risk. Long-acting injectable (LAI) formulations of risperidone and paliperidone carry a similar risk profile to their oral equivalents.

• Moderate or lower risk: Olanzapine is generally associated with mild, transient prolactin elevation. Lurasidone and cariprazine appear to have a lesser effect on prolactin.

• Prolactin-sparing agents: Clozapine and quetiapine are considered prolactin-sparing. Aripiprazole, as a partial D2 agonist, may actually lower prolactin levels and is sometimes used to counteract hyperprolactinaemia caused by other antipsychotics (see Management section).

It is also worth noting that antipsychotic-related weight gain can lead to pseudogynaecomastia — fatty tissue accumulation in the chest — which is distinct from true hormonally driven gynaecomastia and requires different management.

Individual susceptibility varies considerably. Factors such as age, body weight, duration of treatment, and dose all influence whether a patient develops gynaecomastia. Not every patient prescribed a prolactin-raising antipsychotic will experience this side effect, but awareness is essential for timely identification and management.

Recognising Symptoms and When to Seek Medical Advice

Key symptoms include breast swelling, a firm subareolar lump, tenderness, and nipple discharge; unilateral breast enlargement in men aged 50 and over requires urgent referral under NICE NG12 to exclude malignancy.

Gynaecomastia caused by antipsychotics can develop gradually, and patients may not immediately connect breast changes to their medication. Early recognition is important both for patient comfort and to rule out other underlying causes.

Symptoms to be aware of include:

• Swelling or enlargement of one or both breasts

• A firm or rubbery lump of tissue beneath the nipple

• Breast tenderness or sensitivity

• Nipple discharge (galactorrhoea), which may occur alongside gynaecomastia

• Psychological distress, embarrassment, or reduced quality of life related to breast changes

It is important to distinguish gynaecomastia — which involves true glandular tissue — from pseudogynaecomastia, which refers to fatty tissue accumulation in the chest area and is not hormonally driven. A clinician can usually differentiate these on examination.

Contact your GP or prescribing clinician promptly if you notice any of the above changes, particularly if you have recently started or had a dose increase of an antipsychotic.

Seek urgent medical attention if:

• Breast swelling is painful, rapidly enlarging, or associated with skin changes

• There is unilateral (one-sided) breast enlargement, which always warrants clinical assessment to exclude malignancy. In line with NICE guideline NG12 (Suspected Cancer: Recognition and Referral), men aged 50 and over with a unilateral, firm subareolar mass — with or without nipple changes such as retraction, skin changes, or discharge — should be referred urgently via the two-week-wait pathway

• Nipple discharge is present, especially if bloodstained

• Symptoms are causing significant distress or affecting daily life

• You develop a new severe headache or visual disturbance alongside breast changes — these may indicate pituitary pathology and require urgent assessment

Whilst antipsychotic-induced gynaecomastia is generally benign, it should never be assumed without proper clinical assessment. A clinician will typically arrange a morning serum prolactin measurement (taken in a calm, stress-minimised setting) as a first-line investigation. If prolactin is elevated, a repeat sample and consideration of macroprolactin (to exclude a benign macroprolactin fraction) is advisable. Where prolactin is markedly elevated or pituitary pathology is suspected, imaging may be required.

A thorough work-up should also include: testosterone, LH, FSH, TSH, liver function tests, and renal function. If a testicular or other tumour is suspected, serum hCG should be measured and testicular examination performed. A full medication and substance review is important, as other drugs — including opioids, spironolactone, finasteride, anti-androgens, and anabolic steroids — and substances such as cannabis can also cause gynaecomastia.

Other underlying causes — including liver disease, thyroid dysfunction, and hypogonadism — must be considered and excluded through appropriate clinical history and investigations.

Management Options and Switching Medications Safely

Primary management involves dose reduction or switching to a prolactin-sparing agent such as quetiapine or aripiprazole; any switch requires careful cross-tapering under psychiatric supervision to prevent relapse.

Once antipsychotic-induced hyperprolactinaemia and gynaecomastia are confirmed, management should be individualised, balancing the need to address the side effect against the risk of destabilising the patient's mental health condition.

The primary management strategies include:

1. Dose reduction: If clinically appropriate, reducing the dose of the offending antipsychotic may lower prolactin levels sufficiently to resolve or improve gynaecomastia. This must be done cautiously and under close psychiatric supervision to avoid relapse.

2. Switching to a prolactin-sparing antipsychotic: Transitioning to an agent such as quetiapine, clozapine, or aripiprazole is often the most effective long-term solution. Aripiprazole has evidence supporting its use as an adjunctive agent — added at low doses alongside the existing antipsychotic — to reduce prolactin levels without requiring a full medication switch. This approach can be particularly useful in patients who are stable on their current regimen. However, it is important to note that this use of aripiprazole is off-label in the UK (it is not licensed for the treatment of hyperprolactinaemia). It should therefore be initiated under specialist oversight, with documented informed consent, and in line with local prescribing policies. The Maudsley Prescribing Guidelines in Psychiatry provide further guidance on this approach.

3. Pharmacological treatment of gynaecomastia: In cases where switching is not feasible, medications such as tamoxifen (an oestrogen receptor antagonist) or anastrozole (an aromatase inhibitor) have been used off-licence to reduce breast tissue. Evidence in antipsychotic-induced cases is limited, and these options should only be considered under specialist guidance. Medical therapy is generally more effective when gynaecomastia has been present for less than 12 months; established, fibrotic gynaecomastia is less likely to respond to pharmacological intervention.

4. Dopamine agonists: Agents such as bromocriptine or cabergoline are generally avoided in people with psychotic disorders, as they carry a significant risk of exacerbating psychosis. If their use is ever considered — for example, in the context of a prolactin-secreting pituitary adenoma — this must be under joint specialist endocrine and psychiatric supervision.

5. Surgical intervention: Persistent, symptomatic gynaecomastia that does not resolve with medication changes may require referral to a breast surgeon. This is typically considered when other approaches have been exhausted.

Referral: Consider referral to endocrinology for persistent hyperprolactinaemia, marked hypogonadism, infertility, or diagnostic uncertainty. Referral to a breast surgery service is appropriate for refractory, symptomatic gynaecomastia.

Any medication switch must be planned carefully. Abrupt discontinuation of antipsychotics carries risks including rebound psychosis, withdrawal symptoms, and cholinergic rebound (particularly with clozapine). A cross-tapering strategy — gradually introducing the new agent whilst slowly reducing the original — is generally preferred. Decisions should always be made collaboratively between the patient, their psychiatrist, and their GP.

If you believe your medication may be causing a side effect, you or your clinician can report this via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. Reporting suspected adverse drug reactions helps improve the safety of medicines for everyone.

Guidance From NHS and NICE on Monitoring and Review

NICE CG178 recommends regular physical health monitoring for patients on antipsychotics, including proactive enquiry about hyperprolactinaemia symptoms such as breast changes and galactorrhoea.

Both NICE and NHS guidance emphasise the importance of proactive monitoring for metabolic and endocrine side effects in patients prescribed antipsychotic medications. Hyperprolactinaemia and its consequences, including gynaecomastia, fall within this remit.

Experiencing these side effects? Our pharmacists can help you navigate them →

NICE guideline CG178 (Psychosis and Schizophrenia in Adults) recommends that patients on antipsychotics receive regular physical health monitoring, including assessment for side effects that may affect adherence and quality of life. Clinicians are advised to ask patients directly about symptoms of hyperprolactinaemia — such as breast changes, galactorrhoea, and sexual dysfunction — as patients may not volunteer this information spontaneously due to embarrassment.

Whilst NICE CG178 does not specify fixed prolactin testing intervals, it is widely recommended in UK clinical practice — including in the Maudsley Prescribing Guidelines — to consider:

• A baseline prolactin level before commencing a prolactin-raising antipsychotic, where practicable

• Repeat prolactin measurement if symptoms of hyperprolactinaemia develop, after dose increases, or periodically during treatment with prolactin-raising agents, in line with local NHS trust or integrated care board protocols

• Assessment of bone health in patients with sustained hyperprolactinaemia and associated hypogonadism, given the risk of reduced bone mineral density; endocrinology input should be considered in such cases

• Regular review of the continued need for the antipsychotic at the lowest effective dose

Specific prolactin monitoring schedules may vary between NHS trusts and should be followed in accordance with local policy.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) have both highlighted prolactin-related side effects in the prescribing information (SmPCs and EPARs) for relevant antipsychotics, reinforcing the need for informed consent and ongoing monitoring. Clinicians and patients can access UK SmPCs for individual antipsychotics via the electronic Medicines Compendium (emc) at medicines.org.uk.

From a patient safety perspective, individuals and their carers should be educated at the point of prescribing about potential hormonal side effects. Shared decision-making is central to NICE's approach — patients should feel empowered to report new symptoms and discuss concerns without fear of having their medication changed without consultation. If gynaecomastia is identified, a structured medication review involving the GP and the community mental health team is the recommended pathway, ensuring that both physical and mental health needs are addressed in a coordinated and evidence-based manner.

Suspected side effects from antipsychotic medications should be reported to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk), which helps regulators identify and act on emerging safety signals.

Frequently Asked Questions